

# Yong-Dong Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1797691/publications.pdf>

Version: 2024-02-01

46  
papers

3,706  
citations

201674

27  
h-index

265206

42  
g-index

46  
all docs

46  
docs citations

46  
times ranked

7566  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector preps. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 24, 280-291.	4.1	5
2	The myokine Fibcd1 is an endogenous determinant of myofiber size and mitigates cancer-induced myofiber atrophy. <i>Nature Communications</i> , 2022, 13, 2370.	12.8	14
3	Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2403-2406.	7.2	8
4	InÂvivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ TÂcell fate decisions. <i>Cell</i> , 2021, 184, 1245-1261.e21.	28.9	68
5	Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CARÂT-cell responses against ALL. <i>Blood</i> , 2021, 138, 122-135.	1.4	28
6	Antagonistic control of myofiber size and muscle protein quality control by the ubiquitin ligase UBR4 during aging. <i>Nature Communications</i> , 2021, 12, 1418.	12.8	30
7	Proteasome stress in skeletal muscle mounts a long-range protective response that delays retinal and brain aging. <i>Cell Metabolism</i> , 2021, 33, 1137-1154.e9.	16.2	45
8	3â™ UTR-truncated HMGA2 overexpression induces non-malignant inÂvivo expansion of hematopoietic stem cells in non-human primates. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 693-701.	4.1	5
9	Metabolic control of TFH cells and humoral immunity by phosphatidylethanolamine. <i>Nature</i> , 2021, 595, 724-729.	27.8	62
10	CRISPR screens unveil signal hubs for nutrient licensing of T cell immunity. <i>Nature</i> , 2021, 600, 308-313.	27.8	36
11	Integrated genomic and proteomic analyses identify stimulus-dependent molecular changes associated with distinct modes of skeletal muscle atrophy. <i>Cell Reports</i> , 2021, 37, 109971.	6.4	32
12	Translational Repression of G3BP in Cancer and Germ Cells Suppresses Stress Granules and Enhances Stress Tolerance. <i>Molecular Cell</i> , 2020, 79, 645-659.e9.	9.7	40
13	Schizophrenia-related microdeletion causes defective ciliary motility and brain ventricle enlargement via microRNA-dependent mechanisms in mice. <i>Nature Communications</i> , 2020, 11, 912.	12.8	25
14	Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma. <i>Cell Reports</i> , 2020, 30, 454-464.e5.	6.4	26
15	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal <i>FLT</i> <i>3â€</i> ITD AML. <i>Clinical and Translational Science</i> , 2019, 12, 641-647.	3.1	12
16	Circadian gene variants and the skeletal muscle circadian clock contribute to the evolutionary divergence in longevity across <i>Drosophila</i> populations. <i>Genome Research</i> , 2019, 29, 1262-1276.	5.5	20
17	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 7320-7330.	7.0	14
18	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. <i>Cancer Research</i> , 2019, 79, 2208-2219.	0.9	15

#	ARTICLE	IF	CITATIONS
19	Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. <i>Nature</i> , 2019, 576, 471-476.	27.8	251
20	Structure and evolution of double minutes in diagnosis and relapse brain tumors. <i>Acta Neuropathologica</i> , 2019, 137, 123-137.	7.7	63
21	Differentiation of human pluripotent stem cells into neurons or cortical organoids requires transcriptional co-regulation by UTX and 53BP1. <i>Nature Neuroscience</i> , 2019, 22, 362-373.	14.8	33
22	PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. <i>Oncogene</i> , 2018, 37, 1991-2007.	5.9	39
23	FBXO11 Activates Erythroid Gene Transcription By Degrading Heterochromatin-Associated Protein BAH1. <i>Blood</i> , 2018, 132, 529-529.	1.4	0
24	The DNA Methylation Maintenance Protein UHRF1 Regulates Fetal Globin Expression Independent of HBG Promoter DNA Methylation. <i>Blood</i> , 2018, 132, 410-410.	1.4	0
25	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. <i>Leukemia and Lymphoma</i> , 2017, 58, 247-250.	1.3	5
26	Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. <i>Cell Reports</i> , 2017, 18, 2907-2917.	6.4	61
27	Lentiviral Transfer of $\beta^3$ -Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine $\beta^2$ -Thalassemia. <i>Molecular Therapy</i> , 2017, 25, 593-605.	8.2	6
28	SPA70 is a potent antagonist of human pregnane X receptor. <i>Nature Communications</i> , 2017, 8, 741.	12.8	82
29	Thalamic miR-338-3p mediates auditory thalamocortical disruption and its late onset in models of 22q11.2 microdeletion. <i>Nature Medicine</i> , 2017, 23, 39-48.	30.7	55
30	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2017, 128, 369-380.	8.2	39
31	Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation. <i>Scientific Reports</i> , 2016, 6, 25996.	3.3	121
32	The orphan nuclear receptor NR4A2 is part of a p53-microRNA-34 network. <i>Scientific Reports</i> , 2016, 6, 25108.	3.3	35
33	A genome-editing strategy to treat $\beta^2$ -hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. <i>Nature Medicine</i> , 2016, 22, 987-990.	30.7	279
34	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. <i>Blood</i> , 2016, 128, 2838-2838.	1.4	0
35	Mito-protective autophagy is impaired in erythroid cells of aged mtDNA-mutator mice. <i>Blood</i> , 2015, 125, 162-174.	1.4	53
36	Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 516-524.	1.4	69

#	ARTICLE	IF	CITATIONS
37	An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes. <i>Nature Genetics</i> , 2015, 47, 878-887.	21.4	62
38	Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes. <i>Cancer Cell</i> , 2015, 27, 712-727.	16.8	74
39	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	21.4	233
40	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 343-356.	16.8	145
41	Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma. <i>Cancer Cell</i> , 2014, 25, 516-529.	16.8	128
42	High-titer foamy virus vector transduction and integration sites of human CD34+ cell-derived SCID-repopulating cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14020.	4.1	14
43	Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 3620-3620.	1.4	0
44	Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. <i>Nature</i> , 2013, 495, 467-473.	27.8	1,249
45	Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD+ Positive Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 5758-5768.	7.0	87
46	Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR-dependent motility in alveolar rhabdomyosarcoma cells. <i>BMC Cancer</i> , 2012, 12, 154.	2.6	38